Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
triptan |
| gptkbp:approvalYear |
2001
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N02CC07
|
| gptkbp:brand |
Frova
|
| gptkbp:CASNumber |
158747-02-5
|
| gptkbp:chemicalClass |
indole derivative
|
| gptkbp:contraindication |
stroke
ischemic heart disease uncontrolled hypertension |
| gptkbp:developedBy |
gptkb:Vernalis
|
| gptkbp:eliminationHalfLife |
26 hours
|
| gptkbp:excretion |
renal
|
| gptkbp:hasMolecularFormula |
C14H17N3O
|
| https://www.w3.org/2000/01/rdf-schema#label |
frovatriptan
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
5-HT1B/1D receptor agonist
|
| gptkbp:metabolism |
hepatic
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:proteinBinding |
15%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
dizziness
fatigue dry mouth |
| gptkbp:synonym |
frovatriptan succinate
|
| gptkbp:usedFor |
migraine
|
| gptkbp:bfsParent |
gptkb:triptans
|
| gptkbp:bfsLayer |
7
|